Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) is set to issue its quarterly earnings data before the market opens on Monday, November 6th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter.

Bellerophon Therapeutics (NASDAQ:BLPH) last issued its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.03. On average, analysts expect Bellerophon Therapeutics to post $-1.18 EPS for the current fiscal year and $-0.98 EPS for the next fiscal year.

Shares of Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) opened at 1.37 on Monday. The company’s market capitalization is $48.65 million. The company has a 50-day moving average of $1.34 and a 200 day moving average of $1.34. Bellerophon Therapeutics, Inc. has a 12 month low of $0.43 and a 12 month high of $1.98.

ILLEGAL ACTIVITY NOTICE: This report was first published by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at

An institutional investor recently raised its position in Bellerophon Therapeutics stock. Vanguard Group Inc. increased its stake in shares of Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) by 52.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 612,641 shares of the biotechnology company’s stock after buying an additional 211,111 shares during the period. Vanguard Group Inc. owned 1.86% of Bellerophon Therapeutics worth $821,000 at the end of the most recent quarter. Institutional investors own 45.86% of the company’s stock.

Several equities research analysts have recently commented on the stock. ValuEngine upgraded shares of Bellerophon Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 8th. Zacks Investment Research upgraded shares of Bellerophon Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a research note on Monday, August 14th.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.

Earnings History for Bellerophon Therapeutics (NASDAQ:BLPH)

Receive News & Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related companies with's FREE daily email newsletter.